- LOGEX’s existing shareholders, founders and Summa Equity will remain invested in the firm
- Thoma Bravo’s investment in LOGEX is the inaugural investment by its Europe-based team
- Thoma Bravo, based in Chicago, is a software investor with over $120bn assets under management
Thoma Bravo will invest in LOGEX, a European healthcare analytics provider. No financial details of the transaction were disclosed.
LOGEX is headquartered in Amsterdam and has over 450 employees.
LOGEX’s existing shareholders, founders, and Summa Equity will remain invested in the firm.
LOGEX will work closely with Thoma Bravo and the executive committee to assist the firm’s European growth and further accelerate innovation in healthcare analytics, according to a release.
“We are excited to partner with LOGEX and its talented team to drive continued innovation and advance its mission to improve European healthcare,” said David Tse, vice-president at Thoma Bravo. “We look forward to leveraging Thoma Bravo’s demonstrated software and operations capabilities to help the company deliver on its plans.”
Thoma Bravo has deployed $11 billion across 11 deals in Europe over the last 12 years, but the investment in LOGEX is the first by its Europe-based team. Thoma Bravo opened an office in London in September 2022, which is its hub for European deals.
Thoma Bravo, based in Chicago, is a software investor that managed over $120 billion in assets as of 30 September 2022. IT invests in growth-oriented companies operating in the software and technology sectors and has offices in Chicago, London, Miami, and San Francisco.
Kirkland & Ellis provided legal counsel and Harris Williams & Co served as financial advisor to Thoma Bravo.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: 
